BRIEF—Acadia falls as FDA takes closer look at PD drug

Shares in US-based Acadia have fallen sharply on news that the US Food and Drug Administration is reviewing its Parkinson’s drug Nuplazid (pimavanserin).

Nuplazid is the only approved drug used to treat hallucinations and delusions associated with the disease.

The FDA said it was “conducting an evaluation of available information about Nuplazid.” A spokesperson added: “This review has been going on for several weeks. We have nothing more to share at this time.”